Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01815385 · ClinicalTrials.gov registry record
Epigenetic and Developmental Effects of In Utero Exposure to Environmental Toxicants
A clinical trial, sponsored by Montefiore Medical Center.
- Completed
- Registry status
- 110
- Enrollment target
NCT01815385 is a clinical trial that has completed, run by Montefiore Medical Center. The registered enrollment target is 110 participants.
The verdict
NCT01815385 has completed, sponsored by Montefiore Medical Center.
- COMPLETED
- Registry status
- 110 participants
- Enrollment target
Study Summary
Metabolic diseases such as obesity and diabetes are modern day epidemics. Early life exposure to an adverse developmental environment, including environmental toxins, are linked to increased susceptibility to obesity, metabolic syndrome and type 2 diabetes. Although the mechanisms underlying the fetal origins of metabolic disease are poorly understood, strong evidence suggests that alterations in the epigenome play a critical role in this process. The central hypothesis of this proposal is that intrauterine exposure to benzo\[a\]pyrene leads to epigenetic changes which will have functional consequences and may be a marker for, or may contribute to, increased susceptibility to adverse outcomes in childhood including increased adiposity and the subsequent development of obesity, metabolic syndrome or diabetes. The goals of this proposal are to: 1) determine benzo\[a\]pyrene levels in umbilical cord blood of newborns, 2) determine whether benzo\[a\]pyrene exposure during pregnancy correlates with early onset of obesity and metabolic disease by examining the children at 12 and 24 months of age, 3) determine whether in utero benzo\[a\]pyrene exposure programs metabolic disease through alterations in DNA methylation and gene expression, and 4) determine the plasticity of the DNA methylation patterns in the same offspring at 12 months of age. The long-term goal of this project is to define biomarkers that identify neonates at "high-risk" for diminished attainment of full health potential, who can then be targeted for preventative measures.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2013-03 |
| Est. Completion | 2020-03-28 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01815385
The ClinicalTrials.gov registry entry for NCT01815385 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Montefiore Medical Center, which has 345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01815385 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01815385 about?
NCT01815385 is a clinical study titled "Epigenetic and Developmental Effects of In Utero Exposure to Environmental Toxicants". Metabolic diseases such as obesity and diabetes are modern day epidemics. Early life exposure to an adverse developmental environment, including environmental toxins, are linked to increased susceptibility to obesity, metabolic syndrome and type 2 diabetes. Although the mechanisms underlying the fet...
What is the current status of trial NCT01815385?
This trial is currently completed. The enrollment target is 110 participants. The study started on 2013-03. Estimated completion is 2020-03-28.
Who is sponsoring clinical trial NCT01815385?
This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.